Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population

Journal of Clinical Oncology

Volumn 27, Issue 4, 2009, Pages 572-578

  Johansen, Julia S ^a   Bojesen, Stig E ^a   Mylin, Anne K ^a   Frikke Schmidt, Ruth ^a   Price, Paul A ^a   Nordestgaard, Børge G ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; UNCLASSIFIED DRUG; YKL 40 PROTEIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; DIGESTIVE SYSTEM CANCER; DISEASE MARKER; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; NEOPLASM; POPULATION RISK; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY TRACT CANCER; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; GASTROINTESTINAL NEOPLASMS; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 59149100287     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.8367     Document Type: Article

References (41)

1. Jemal AJ, Siegel R, Ward E, et al: Cancer Statistics, 2008. CA Cancer J Clin 58:71-96, 2008
2. Johansen JS, Jensen BV, Roslind A, et al: Serum YKL-40: A new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 15:194-202, 2006
3. Cintin C, Johansen JS, Christensen IJ, et al: High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 95:267-274, 2002
4. Jensen BV, Johansen JS, Price PA: High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 9:4423-4434, 2003
5. Dupont J, Tanwar MK, Thaler HT, et al: Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 22:3330-3339, 2004
6. Schmidt H, Johansen JS, Sjoegren P, et al: Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol 24:798-804, 2006
7. Hormigo A, Gu B, Karimi S, et al: YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12:5698-5704, 2006
8. Johansen JS, Brasso K, Iversen P, et al: Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res 13:3244-3249, 2007
9. Roslind A, Johansen JS, Christensen IJ, et al: High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int J Cancer 122:857-863, 2008
10. Bussink AP, Speijer D, Aerts JMFG, et al: Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases. Genetics 177:959-970, 2007
11. Schnohr P, Jensen JS, Scharling H, et al: Coronary heart disease risk factors ranked by importance for the individual and community: A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study. Eur Heart J 23:620-626, 2002
12. Bojesen SE, Tybjærg-Hansen A, Nordestgaard BG: Integrin β3 leu33pro homozygosity and risk of cancer. J Natl Cancer Inst 95:1150-1157, 2003
13. Nordestgaard BG, Benn M, Schnohr P, et al: Nonfasting trigycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299-308, 2007
14. Ørsted DD, Bojesen SE, Tybjærg-Hansen A, et al: Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J Exp Med 204:1295-1301, 2007
15. Harvey S, Weisman M, O'Dell J, et al: Chondrex: New marker of joint disease. Clin Chem 44:509-516, 1998
16. Kamstrup PR, Benn M, Tybjærg-Hansen A, et al: Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The Copenhagen City Heart Study. Circulation 117:176-184, 2008
17. Clarke R, Shipley M, Lewington S, et al: Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 150:341-353, 1999
18. Ringsholt M, Høgdall EVS, Johansen JS, et al: YKL-40 protein expression in normal human tissues: An immunohistochemical study. J Mol Histol 38:33-43, 2007
19. Junker N, Johansen JS, Andersen CB, et al: Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 48:223-231, 2005
20. Volck B, Price PA, Johansen JS, et al: YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 110:351-360, 1998
21. Johansen JS, Høyer PE, Larsen LA, et al: YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem 55:1213-1228, 2007
22. Pelloski CE, Lin E, Zhang L, et al: Prognostic associations of activated mitogen-activated protein kinase and akt pathways in glioblastoma. Clin Cancer Res 12:3935-3941, 2006
23. Johansen JS: Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibrosis and cancer. Dan Med Bull 53:172-209, 2006
24. Chupp GL, Lee CG, Jarjour N, et al: A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 357:2016-2027, 2007
25. Dickey BF: Exoskeletons and exhalation. N Engl J Med 357:2082-2084, 2007
26. Kawada M, Chen C-C, Arihiro A, et al: Chitinase 3-like-1 enhances bacterial adhesion to colonic epithelial cells through the interaction with bacterial chitin-binding protein. Lab Invest 88:883-895, 2008
27. Coussens LM, Werb Z: Inflammation and cancer. Nature 420:860-867, 2002
28. Balkwill F, Charles KA, Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211-217, 2005
29. de Visser KE, Eichten A, Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24-37, 2006
30. Lin W-W, Karin M: A cytokine-mediated link between immunity, inflammation, and cancer. J Clin Invest 117:1175-1183, 2007
31. Shackelton LM, Mann DM, Millis AJT: Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodelling. J Biol Chem 270:13076-13083, 1995
32. Malinda KM, Ponce L, Kleinman HK, et al: Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250:168-173, 1999
33. Nishikawa KC, Millis AJT: Gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 287:79-87, 2003
34. Saidi A, Javerzat S, Bellahcene A, et al: Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer 122:2187-2198, 2008
35. Recklies AD, White C, Ling H: The chitinase 3-like protein human cartilage 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase-and protein kinase B-mediated signaling pathways. Biochem J 365:119-126, 2002
36. Hillen F, Griffioen AW: Tumour vascularization: Sprouting angiogenesis and beyond. Cancer Metastasis Rev 26:489-502, 2007
37. Tlsty TD, Coussens LM: Tumor stroma and regulation of cancer development. Annu Rev Pathol Mech Dis 1:119-150, 2006
38. Johansen JS, Lottenburger T, Nielsen HJ, et al: Diurnal, weekly and long time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev 17:2603-2608, 2008
39. Johansen JS, Pedersen AN, Schroll M, et al: High serum YKL-40 level in a cohort of 80-years old is associated with increased risk of all-cause mortality. Clin Exp Immunol 151:260-266, 2008
40. Nøjgaard C, Johansen JS, Christensen E, et al: Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 39:179-186, 2003
41. Jensen MK, Sørensen TIA, Andersen AT, et al: A prospective study of the association between smoking and later alcohol drinking in the general population. Addiction 98:355-363, 2003